Treatment Using Donor-Derived Viral Specific T-cells for Viral Infections After Allogeneic Stem Cell Transplant

What this Trial Is About

This research investigates the use of donor-derived viral specific T-cells VSTs to treat viral infections occurring after allogeneic stem cell transplant. Viral infections such as cytomegalovirus, Epstein-Barr virus, adenovirus, BK virus, and JC virus are common complications following transplant and can cause serious health issues. The study aims to find an easier and potentially safer way to manage these infections, which currently require prolonged and sometimes toxic antiviral treatments. The donor who matches the stem cell transplant recipient will provide a blood sample to create the VSTs in the lab. These cells are grown and stored in a freezer until needed. If the patient shows signs of viral infection after transplant, they may receive up to five infusions of these virus-fighting cells spaced 14 to 21 days apart. The cells are given to help the patients immune system fight the virus, and more infusions may be given based on the patients response. During the study, patients will be closely monitored with physical exams and blood tests both in the hospital and outpatient settings. Blood and urine samples will be collected before each infusion and regularly for up to a year after the final infusion. Researchers will assess how well the VSTs are produced, any infusion-related side effects, and the presence of viral infections. The goal is to evaluate the safety and viral response to this treatment over time.

Donor-Derived Viral Specific T-cells (VSTs)